Tonix Pharmaceuticals Holding Corp. announced that its management team will present and host investor meetings at multiple January investor conferences, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, both held in San Francisco. President and Chief Executive Officer Seth Lederman, M.D., is scheduled to deliver a company presentation and participate in a panel discussion focused on neuropsychiatric drug development at the Sachs Associates forum, and to present at Biotech Showcase 2026, with a replay of the presentation expected to be made available on the company's website following the event.
The company's presentation will highlight Tonix as a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix markets FDA-approved TONMYA, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. TONMYA is the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. TONMYA was investigated as TNX-102 SL. Tonix also markets two treatments for acute migraine in adults: Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray).
Tonix's development portfolio is focused on central nervous system disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense. TNX-102 SL is also in development for major depressive disorder. Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a Phase 2-ready Fc-modified humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.
The company's rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study in 2026. Tonix's infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a Phase 2-ready long-acting humanized monoclonal antibody for the seasonal prevention of Lyme disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD's Defense Threat Reduction Agency for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of high lethality infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.
The investor conference presentations provide an opportunity for the biotechnology company to showcase its diversified pipeline to potential investors and industry partners. With multiple development candidates across various therapeutic areas and both commercial products and government-funded research programs, Tonix represents a company with multiple potential value drivers. The company's focus on CNS disorders comes at a time when mental health and neurological conditions are receiving increased attention from both the medical community and regulatory agencies. The infectious disease portfolio, particularly the government-funded TNX-4200 program, demonstrates the company's capability to address public health threats with potential military and civilian applications.
For investors and industry observers, these presentations offer insight into a biotechnology company with both near-term commercial assets and long-term development potential across multiple high-need therapeutic areas. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Additional information about the company is available through its newsroom at https://ibn.fm/TNXP.
